Eaton Vance Management Allogene Therapeutics, Inc. Transaction History
Eaton Vance Management
- $67.5 Billion
- Q3 2022
A detailed history of Eaton Vance Management transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Eaton Vance Management holds 237,155 shares of ALLO stock, worth $552,571. This represents 0.0% of its overall portfolio holdings.
Number of Shares
237,155
Previous 237,155
-0.0%
Holding current value
$552,571
Previous $2.7 Million
5.29%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ALLO
# of Institutions
164Shares Held
106MCall Options Held
97.5KPut Options Held
45.6K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$43.6 Million1.76% of portfolio
-
Black Rock Inc. New York, NY9.65MShares$22.5 Million0.0% of portfolio
-
State Street Corp Boston, MA9.18MShares$21.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.21MShares$19.1 Million0.0% of portfolio
-
Primecap Management CO Pasadena, CA5.45MShares$12.7 Million0.02% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $335M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...